ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease

First head-to-head study of ARICEPT (donepezil hydrochloride) and Exelon (rivastigmine tartrate) offers comparative information of clinical use to physicians

Study patients treated according to approved product labeling

NEW YORK, SEPTEMBER 27, 2000 - Results from the first head-to-head study between ARICEPT (donepezil hydrochloride) (Eisai and Pfizer Inc) and Exelon (rivastigmine tartrate) (Novartis Pharma AG) showed that in this open-label study ARICEPT was better tolerated than Exelon in patients with mild to moderate Alzheimers disease. Data were presented at a scientific conference earlier this month in Munich, Germany.

"Despite the often devastating nature of the disease, tolerability is still very important to patients with Alzheimer's disease," said David Wilkinson, MD, director of the Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, England, and an investigator in the study. Patients tend to be elderly and often have other medical conditions that can make treating Alzheimers disease more complex. It is therefore important to treat patients with medications that are well tolerated and easy to use, such as ARICEPT.

The multinational, head-to-head, open-label study was designed to compare the tolerability and ease of use of ARICEPT to Exelon in 111 patients with mild to moderate Alzheimers disease.

The two treatment groups had similar improvements from baseline in Alzheimers Disease Assessment Scale-cognitive subscale (ADAS-cog) scores throughout the 12-week treatment period. ADAS-cog is a clinically validated measure of cognitive function. Testing was administered by independent raters who were blinded to study medication.

Key study findings:

  • Almost 4 times as many patients in the Exelon (rivastigmine tartrate)-treatment group reported nausea compared with the ARICEPT (donepezil hydrochloride)-treatment group (41.8% vs 10.7%). '"/>

Contact: Celeste Torello, Pfizer Inc.
Porter Novelli

Page: 1 2 3 4

Related medicine news :

1. ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients
2. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
3. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
4. Do minorities survive hospitalization better than others?
5. Boston University team finds link between high cholesterol and better cognitive performance
6. Specialist care gives better rate of survival
7. Balance and better interactions between primary-care and specialist physicians improve US health
8. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
9. Pet scanning better for heart disease diagnosis, management
10. Laughter helps blood vessels function better
11. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer

Post Your Comments:

(Date:8/15/2019)... ... , ... Heritage Woods of Rockford Administrator Jaclyn O’Keefe has been named Administrator ... is part of the NCAL Awards Program, which recognizes exemplary assisted living caregivers. Honorees ... year’s recipients is that they all go out of their way to ensure assisted ...
(Date:8/14/2019)... ... , ... New Hampshire-based Vera Roasting Company , makers of the only ... line of CBD-infused coffees with the release of a new higher-dosage organic Wellness ... “We are excited to expand our CBD-infused product lines to include a more potent ...
(Date:8/14/2019)... ... ... Today, consumers are taking a harder look at what goes into their bodies. ... levels. The trick is finding food and beverages that are delicious and nutritious to ... created Chase – a delicious, guilt free cocktail mixer that doesn’t compromise ...
(Date:8/12/2019)... ... August 12, 2019 , ... Injured ... to donations received through the 4th annual Lockton Warfighter Sports Charity Challenge being ... , Participating in the event again this year will be fifty ...
(Date:8/9/2019)... ... August 09, 2019 , ... ... its second opioid treatment program (OTP) in Ohio. MedMark Lebanon will provide medically-supervised ... The clinic, located at 1521 Walmart Drive, is now accepting patients. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2019)... , ... August 15, 2019 , ... Men’s Health Memorial ... with health care experts and learn how to regain their strength and vitality. ... taking the first step to do something about it is not always easy,” said ...
(Date:8/15/2019)... ... 2019 , ... Inc. magazine revealed that Skysis is No. ... nation’s fastest-growing private companies. The list represents a unique look at the most ... Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names ...
(Date:8/14/2019)... ANDOVER, Mass. (PRWEB) , ... August 14, 2019 ... ... Andover, Massachusetts, is continuing its research and development of its drug platform GVT ... Illness (GWI), ALS, and Parkinson’s disease among others. Overwhelming data from multiple animal ...
Breaking Medicine Technology:
Cached News: